Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters

  • Lim, Sung-Yoon (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Sun-Won (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Eung-Ju (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kang, Jun-Hyuk (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Su-A (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Yun-Kyung (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Na, Jin-Oh (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Choi, Cheol-Ung (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Lim, Hong-Euy (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Han, Seong-Woo (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Rha, Seung-Woon (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Park, Chang-Gyu (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Seo, Hong-Seog (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Oh, Dong-Joo (Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine)
  • Published : 2011.10.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have been conducted with different ARBs. We compared these effects in patients with uncomplicated hypertension who were receiving telmisartan or valsartan. Subjects and Methods: The subjects were patients with essential hypertension (48.4${\pm}$9.6 years) who were randomly assigned to take either telmisartan (80 mg/day, n=30) or valsartan (160 mg/day, n=30) for 12 weeks. Their anthropometric, laboratory, vascular, and echocardiographic data were measured at baseline and at the end of the study. Results: Baseline characteristics were not significantly different between the two groups, except for the carotid-femoral pulse wave velocity (cfPWV; telmisartan group vs. valsartan group; 841.2${\pm}$131.0 vs. 761.1${\pm}$104.4 cm/s, p<0.05). After 12 weeks, BP had fallen to a similar extent with mean reductions in the systolic and diastolic BP of 20.7${\pm}$18.1 and 16.3${\pm}$13.0 mm Hg (p<0.001, respectively) for the telmisartan and 22.5${\pm}$17.0 and 16.8${\pm}$9.3 mm Hg (p<0.001, respectively) for the valsartan group. Although the cfPWV and left ventricular mass index (LVMI) fell significantly only with the administration of telmisartan, they were not significantly different when baseline cfPWV was considered. The differences in the cfPWV and LVMI changes from baseline between the two groups were also not significant after adjusting for baseline cfPWV. No sig-nificant changes in other vascular, metabolic, or inflammatory parameters were observed with either treatment. Conclusion: The effects of a 12-week treatment with the two ARBs, telmisartan and valsartan, on cardiovascular, metabolic, and inflammatory parameters were not different in patients with uncomplicated hypertension.

Keywords

References

  1. Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol Hypertens 2005;14:435-41. https://doi.org/10.1097/01.mnh.0000174397.59100.89
  2. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
  3. Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009;39:180-4. https://doi.org/10.4070/kcj.2009.39.5.180
  4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. https://doi.org/10.1056/NEJM200001203420301
  5. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3
  6. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002. https://doi.org/10.1161/01.HYP.0000123072.34629.57
  7. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7. https://doi.org/10.1161/01.CIR.0000127955.36250.65
  8. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001;103:448-54. https://doi.org/10.1161/01.CIR.103.3.448
  9. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10. https://doi.org/10.1016/S0735-1097(03)00846-5
  10. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7. https://doi.org/10.1161/01.CIR.0000140265.21608.8E
  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. https://doi.org/10.1007/BF00280883
  12. Hwang WM, Bae JH, Kim KY, Synn YC. Impacts of atherosclerotic coronary risk factors on atherosclerotic surrogates in patients with coronary artery disease. Korean Circ J 2005;35:131-9.
  13. Safar ME, Smulyan H. Measurements of arterial stiffness: are they ready for clinical use? Current Cardiovascular Risk Reports 2008;2:268-73, doi: 10.1007/s12170-008-0050-z.
  14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
  15. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. https://doi.org/10.1016/0002-9149(86)90771-X
  16. Kim KI, Kim Y, Kim HJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean Epidemiology Study on Hypertension (KEY study). Am J Hypertens 2008;21:884-9. https://doi.org/10.1038/ajh.2008.191
  17. Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin 2010;26:213-22. https://doi.org/10.1185/03007990903444434
  18. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-7. https://doi.org/10.1097/00126097-200306000-00004
  19. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10. https://doi.org/10.1097/00126097-200408000-00005
  20. Song HG, Kim EJ, Seo HS, et al. Relative contributions of different cardiovascular risk factors to significant arterial stiffness. Int J Cardiol 2010;139:263-8. https://doi.org/10.1016/j.ijcard.2008.10.032
  21. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9. https://doi.org/10.1016/j.amjhyper.2005.08.007
  22. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-23. https://doi.org/10.1161/HYPERTENSIONAHA.108.111674
  23. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6. https://doi.org/10.1097/01.hjh.0000160211.56103.48
  24. Yamamoto K, Mano T, Yoshida J, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005;23:393-400. https://doi.org/10.1097/00004872-200502000-00022
  25. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96: 4002-10. https://doi.org/10.1161/01.CIR.96.11.4002
  26. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004;110:552-7. https://doi.org/10.1161/01.CIR.0000137118.47943.5C
  27. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. https://doi.org/10.1016/j.echo.2005.10.005

Cited by

  1. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction vol.36, pp.7, 2011, https://doi.org/10.1038/hr.2012.233
  2. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO) vol.10, pp.1, 2013, https://doi.org/10.1177/1479164112444640
  3. Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study vol.37, pp.1, 2011, https://doi.org/10.1038/hr.2013.112
  4. A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation vol.37, pp.9, 2011, https://doi.org/10.1038/hr.2014.81